We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$8.55B
$45.4M 8.44%
939,669
-80,664
-8% -$3.38M
BOXX icon
2
Alpha Architect 1-3 Month Box ETF
BOXX
$13.1B
$37.6M 6.98%
337,125
+11,675
+4% +$1.3M
ROIV icon
3
Roivant Sciences
ROIV
$23.6B
$35.1M 6.52%
3,483,404
-25,290
-0.7% -$273K
ZLAB icon
4
Zai Lab
ZLAB
$2.07B
$34M 6.31%
940,858
-104,979
-10% -$3.23M
IMVT icon
5
Immunovant
IMVT
$7.93B
$16.6M 3.07%
968,866
+181,388
+23% +$3.79M
CYTK icon
6
Cytokinetics
CYTK
$10.6B
$15.7M 2.92%
390,729
-23,480
-6% -$1.08M
KROS icon
7
Keros Therapeutics
KROS
$197M
$15.1M 2.81%
1,486,461
+1,463,215
+6,294% +$17M
ABVX
8
Abivax
ABVX
$10.4B
$13.8M 2.56%
2,210,019
+696,626
+46% +$4.71M
BIL icon
9
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
$12.4M 2.31%
135,585
+3,799
+3% +$348K
BBIO icon
10
BridgeBio Pharma
BBIO
$16.4B
$11.7M 2.18%
339,635
-339,222
-50% -$11.4M
IKT icon
11
Inhibikase Therapeutics
IKT
$347M
$11.2M 2.08%
5,122,105
+19,100
+0.4% +$48K
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
$9.17M 1.7%
+207,778
New +$9.56M
SHY icon
13
iShares 1-3 Year Treasury Bond ETF
SHY
$25.4B
$8.55M 1.59%
+103,337
New +$8.5M
TEVA icon
14
Teva Pharmaceuticals
TEVA
$40.4B
$8.05M 1.49%
523,767
+377,096
+257% +$6.74M
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.64B
$7.84M 1.46%
122,921
+82,919
+207% +$8.73M
PCSC
16
DELISTED
Perceptive Capital Solutions
PCSC
$7.72M 1.43%
750,000
– –
CGON icon
17
CG Oncology
CGON
$6.1B
$7.37M 1.37%
301,134
+85,384
+40% +$2.4M
RAPT
18
DELISTED
RAPT Therapeutics
RAPT
$7.28M 1.35%
746,346
+599,557
+408% +$5.9M
JANX icon
19
CALL
Janux Therapeutics
JANX
$912M
$7.15M 1.33%
+264,900
New +$9.99M
ABUS icon
20
Arbutus Biopharma
ABUS
$847M
$6.56M 1.22%
1,879,114
+324,312
+21% +$1.08M
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.34M 1.18%
+48,044
New +$5.99M
RVMD icon
22
Revolution Medicines
RVMD
$38.5B
$6.26M 1.16%
177,136
+7,136
+4% +$290K
AVR
23
Anteris Technologies
AVR
$769M
$6.11M 1.13%
1,678,063
+625,095
+59% +$4.02M
AAM
24
DELISTED
AA Mission Acquisition Corp
AAM
$6.03M 1.12%
578,359
+18,160
+3% +$185K
SAGE
25
DELISTED
Sage Therapeutics
SAGE
$5.9M 1.1%
742,495
+723,295
+3,767% +$5.3M
1
2 3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.